Pardi Elena, Poma Anello Marcello, Torregrossa Liborio, Pierotti Laura, Borsari Simona, Della Valentina Simone, Marcocci Claudio, Cetani Filomena
Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy.
J Clin Endocrinol Metab. 2024 Dec 18;110(1):48-58. doi: 10.1210/clinem/dgae441.
Atypical parathyroid tumor (APT) represents a neoplasm characterized by histological features typical of parathyroid carcinoma (PC) but lacking local infiltration and/or distant metastasis, leading to uncertainty regarding its malignant potential.
To characterize the molecular landscape and deregulated pathways in APT.
Whole-exome sequencing (WES) was conducted on 16 APTs. DNA from tumors and matched peripheral blood underwent WES using Illumina HiSeq3000.
A total of 192 nonsynonymous variants were identified. The median number of protein-altering mutations was 9. The most frequently mutated genes included BCOR, CLMN, EZH1, JAM2, KRTAP13-3, MUC16, MUC19, and OR1S1. Seventeen mutated genes belong to the Cancer Gene Census list. The most consistent hub genes identified through STRING network analysis were ATM, COL4A5, EZH2, MED12, MEN1, MTOR, PI3, PIK3CA, PIK3CB, and UBR5. Deregulated pathways included the PI3 K/AKT/mTOR pathway, Wnt signaling, and extracellular matrix organization. Variants in genes such as MEN1, CDC73, EZH2, PIK3CA, and MTOR, previously reported as established or putative/candidate driver genes in benign adenoma (PA) and/or PC, were also identified in APT.
APT does not appear to have a specific molecular signature but shares genomic alterations with both PA and PC. The incidence of CDC73 mutations is low, and it remains unclear whether these mutations are associated with a higher risk of recurrence. Our study confirms that PI3 K/AKT/mTOR and Wnt signaling represents the pivotal pathways in parathyroid tumorigenesis and also revealed mutations in key epigenetic modifier genes (BCOR, KDM2A, MBD4, and EZH2) involved in chromatin remodeling, DNA, and histone methylation.
非典型甲状旁腺肿瘤(APT)是一种肿瘤,其组织学特征与甲状旁腺癌(PC)典型特征相符,但缺乏局部浸润和/或远处转移,导致其恶性潜能存在不确定性。
描述APT的分子图谱和失调通路。
对16例APT进行全外显子测序(WES)。使用Illumina HiSeq3000对肿瘤组织和配对的外周血DNA进行WES。
共鉴定出192个非同义变异。蛋白质改变突变的中位数为9个。最常发生突变的基因包括BCOR、CLMN、EZH1、JAM2、KRTAP13-3、MUC16、MUC19和OR1S1。17个突变基因属于癌症基因普查列表。通过STRING网络分析确定的最一致的中心基因是ATM、COL4A5、EZH2、MED12、MEN1、MTOR、PI3、PIK3CA、PIK3CB和UBR5。失调的通路包括PI3K/AKT/mTOR通路、Wnt信号通路和细胞外基质组织。在APT中也鉴定出了先前报道为良性腺瘤(PA)和/或PC中已确定的或推定的/候选驱动基因的基因变异,如MEN1、CDC73、EZH2、PIK3CA和MTOR。
APT似乎没有特定的分子特征,但与PA和PC都存在基因组改变。CDC73突变的发生率较低,目前尚不清楚这些突变是否与更高的复发风险相关。我们的研究证实PI3K/AKT/mTOR和Wnt信号通路是甲状旁腺肿瘤发生的关键通路,并且还揭示了参与染色质重塑、DNA和组蛋白甲基化的关键表观遗传修饰基因(BCOR、KDM2A、MBD4和EZH2)中的突变。